L-3,4-二氟苯丙氨酸 | 31105-90-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: L-3,4-二氟苯丙氨酸
• 中文别名: 3,4-二氟-L-苯基丙氨酸
• 英文名称: (S)-2-amino-3-(3,4-difluorophenyl)propanoic acid
• 英文别名: 3,4-difluorophenylalanine；(L)-2-amino-3-(3,4-difluorophenyl)propanoic acid；D-(3,4)-difluorophenylalanine；L-(3,4)-difluorophenylalanine；(2S)-2-azaniumyl-3-(3,4-difluorophenyl)propanoate
• CAS: 31105-90-5
• 化学式: C₉H₉F₂NO₂
• 分子量: 201.173
• InChiKey: PRAWYXDDKCVZTL-QMMMGPOBSA-N

物化性质

• 沸点：
  311.9±42.0 °C(Predicted)
• 密度：
  1.379±0.06 g/cm3 (20 ºC 760 Torr)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，也未有已知危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2922499990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3,4-Difluoro-l-phenylalanine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3,4-Difluoro-l-phenylalanine
CAS number: 31105-90-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9F2NO2
Molecular weight: 201.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  L-3,4-二氟苯丙氨酸 在 氯化亚砜 、 C₃₈H₄₀ClN₂O₃RhS 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.17h， 生成 N-((2S,3S)-4-chloro-1-(3,4-difluorophenyl)-3-hydroxybutan-2-yl)benzamide
  参考文献：
  名称：

  Rh（iii）催化的非对映选择性转移氢化：有效进入HIV蛋白酶抑制剂的关键中间体。

  摘要：

  开发了一种由束缚的铑配合物催化的α-氨基烷基α'-氯甲基酮的高效非对映选择性转移加氢反应，并成功地用于HIV蛋白酶抑制剂关键中间体的合成中。使用当前的Rh（iii）催化剂系统，可以以优异的收率和非对映选择性（最高99％收率，最高99：1 dr）生产一系列手性3-氨基-1-氯-2-羟基-4-苯基丁烷。通过使用Rh（iii）催化剂的两种对映异构体，可以有效地获得所需产物的两种非对映异构体。

  DOI：

  10.1039/c9cc09793g
• 作为产物：
  描述：

  2-Acetamido-2-[(3,4-difluorophenyl)methyl]propanedioic acid 在 sodium hydroxide 、 Aspergillus genus acylase 、 sodium acetate 作用下， 以 对二甲苯 、 水 为溶剂， 反应 50.0h， 生成 L-3,4-二氟苯丙氨酸
  参考文献：
  名称：

  Synthesis of a complete set of l-difluorophenylalanines, l-(F2)Phe, as molecular explorers for the CH/π interaction between peptide ligand and receptor

  摘要：

  A complete set of difluorophenylalanines in the L-configuration [L-(F-2)Phe] (namely, L-(2,3-F-2)Phe, L-(2,4F(2))Phe, L-(2,5-F-2)Phe, L-(2,6-F-2)Phe, L-(3,4-F-2)Phe, L-(3,5-F-2)Phe) was prepared and incorporated into the thrombin receptor-tethered ligand peptide SFLLRNP to identify the phenyl hydrogens of the Phe-2 residue involved in the CH/pi receptor interaction. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)02191-7

文献信息

• [EN] BACKBONE-CYCLIZED PEPTIDOMIMETICS<br/>[FR] PEPTIDOMIMÉTIQUES À SQUELETTE CYCLISÉ
  申请人：POLYPHOR AG

  公开号：WO2016162127A1

  公开（公告）日：2016-10-13

  Novel backbone-cyclized peptidomimetics of the general formula cyclo[-P1-P2-P3-P4-P5-P6-P7-P8-T1-T2-] (I) wherein the single elements T or P are α-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property to modulate the GLP-1 receptor. They can be used as medicaments to treat, prevent, or delay the onset of diseases, disorders or conditions in which modulation of the human GLP-1 receptor is beneficial, such as type 2 diabetes. These backbone-cyclized peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.

  新型的骨架环化肽类似物的一般公式为cyclo[-P1-P2-P3-P4-P5-P6-P7-P8-T1-T2-]（I），其中单个元素T或P是α-氨基酸残基，以任一方向连接，根据它们在链中的位置，在描述和权利要求中定义，以及其盐，具有调节GLP-1受体的特性。它们可用作药物治疗、预防或延缓调节人类GLP-1受体有益的疾病、紊乱或病况，如2型糖尿病。这些骨架环化肽类似物可通过基于混合固相和溶液相合成策略的过程制造。
• [EN] AZASULFURYLPEPTIDE-BASED CD36 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS CD36 À BASE D'AZASULFURYLPEPTIDES ET UTILISATIONS DE CEUX-CI
  申请人：RSEM LTD PARTNERSHIP

  公开号：WO2016029324A1

  公开（公告）日：2016-03-03

  Novel azasulfuryl-containing peptidomimetics capable of inhibiting CD36 activity are disclosed. Use of these azasulfuryl-containing peptidomimetics for the treatment of CD36-related diseases, disorders or conditions, including TLR2-mediated inflammatory disease, disorder or condition, and methods of obtaining such azasulfuryl-containing peptidomimetics, are also disclosed.

  揭示了能够抑制CD36活性的新型含氮硫酰基的肽类模拟物。还揭示了利用这些含氮硫酰基的肽类模拟物治疗与CD36相关的疾病、紊乱或状况，包括TLR2介导的炎症性疾病、紊乱或状况的用途，以及获取这种含氮硫酰基的肽类模拟物的方法。
• Substituted anilinic piperidines as MCH selective antagonists
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06727264B1

  公开（公告）日：2004-04-27

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  这项发明涉及对黑素集中激素-1（MCH1）受体具有选择性的拮抗剂化合物。发明提供了一种药物组合物，包括治疗有效量的本发明化合物和药用可接受载体。本发明还提供了一种通过结合本发明的治疗有效量的化合物和药用可接受载体来制造的药物组合物。本发明进一步提供了一种制造药物组合物的方法，包括结合治疗有效量的本发明化合物和药用可接受载体。
• GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF
  申请人：RISEN (SUZHOU) PHARMA TECH CO., LTD.

  公开号：US20190185502A1

  公开（公告）日：2019-06-20

  There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.

  提供了化合物A的公式及其药用盐和酯，以及用于哺乳动物关节和骨骼疾病（如关节炎和骨质疏松症）的预防或治疗的药物组合物。
• Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
  申请人：DEVELOPMENT CENTER FOR BIOTECHNOLOGY

  公开号：US20030229017A1

  公开（公告）日：2003-12-11

  A solid phase synthesis method for preparing peptide-spacer-lipid conjugates, the peptide-spacer-lipid conjugates synthesized by the method, and liposomes containing the peptide-spacer-lipid conjugates. The present invention provides a convenient solid phase synthesis method for preparing peptide-spacer-lipid conjugates and provides various linkage groups (such as amide group) for conjugating peptide, spacer and lipid, wherein the spacer may comprise PEG. Several advantages can be achieved, such as the synthetic procedure can be simplified, the synthesis process can be set to automation, the purification is easier in each reaction step, and the product losses can be reduced to minimal during synthesis. The present synthesis method is suitable for preparing a wide range of peptide-spacer-lipid conjugates, provides a peptide-spacer-lipid conjugate prepared by the solid phase synthesis method of the present invention, which can be incorporated into a liposome as the targeting moiety for liposomal drug delivery to specific cells, and provides a targeting liposome containing the present peptide-spacer-lipid conjugate.

  一种用于制备肽-间隔子-脂质共轭物的固相合成方法，所述方法合成的肽-间隔子-脂质共轭物，以及含有肽-间隔子-脂质共轭物的脂质体。本发明提供了一种便利的固相合成方法，用于制备肽-间隔子-脂质共轭物，并提供了各种连接基团（如酰胺基团）用于连接肽、间隔子和脂质，其中间隔子可以包括PEG。可以实现几项优点，例如合成过程可以简化，合成过程可以设定为自动化，每个反应步骤中的纯化更容易，并且在合成过程中产品损失可以降至最低。本合成方法适用于制备各种肽-间隔子-脂质共轭物，提供了一种由本发明的固相合成方法制备的肽-间隔子-脂质共轭物，可作为靶向单元被纳入脂质体，用于将脂质体药物传递到特定细胞，并提供了含有本肽-间隔子-脂质共轭物的靶向脂质体。